Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/13/2008

hase III clinical trials of JZP-6 (sodium

oxybate) in fibromyalgia. The enrollment goal of 525 subjects has

been achieved in the first trial, and enrollment is expected to be

completed in the next several weeks. Top-line results for the first

trial are expected in the fourth quarter of 2008. Enrollment is

progressing in the second Phase III clinical trial of JZP-6 at

clinical sites in the U.S. and Europe.

-- On March 18, 2008, Jazz Pharmaceuticals announced the expansion of its

senior term debt under an agreement with an affiliate of Lehman

Brothers and certain other lenders. The transaction closed with

$40 million of gross proceeds, expanding the senior debt outstanding

from $80 million to $120 million. Jazz Pharmaceuticals has an option

under the agreement, through January 31, 2009, to borrow an additional

$30 million if sales of the company's products reach certain levels by

the end of 2008.

-- On May 8, 2008, Jazz Pharmaceuticals announced it had entered into a

Committed Equity Financing Facility (CEFF) with Kingsbridge Capital

Limited, a private investment group, in which Kingsbridge committed to

provide up to $75 million of capital through the purchase of

newly-issued shares of Jazz Pharmaceuticals' common stock. Under the

terms of the three-year agreement, Jazz Pharmaceuticals will determine

the exact timing and amount of any CEFF financings, subject to certain

conditions. The arrangement allows Jazz Pharmaceuticals to raise

capital, at its discretion, to support the company's commercial,

research and development and general corporate activities.

Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss its financial results and provide a business update on its commercial and devel
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medimetriks Pharmaceuticals, Inc. Begins Operations
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
5. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
6. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
7. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
8. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
9. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
10. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
11. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... 13 Proteon Therapeutics is,presenting new data ... potential of PRT-201 to enhance outcomes in ... (PAD). The,presentation, entitled, "Local Catheter-Directed Elastase Therapy: ... is being made at the 20th,annual Transcatheter ...
... CLARA, Calif., Oct. 13 WebLOQ, Inc., ... secure and compliant eBusiness and,data-in-motion communications, today ... the WebLOQ ePrivacy solution in their state-of-the-art,Monterey ... partner, the,Monterey Peninsula Surgery Center, and other ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
Cached Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 3
(Date:9/2/2014)... may have discovered a new way of harnessing lupus ... DNA repair. , The findings were published recently in ... study, led by James E. Hansen, M.D., assistant professor ... that cancer cells with deficient DNA repair mechanisms (or ... significantly more vulnerable to attack by lupus antibodies. , ...
(Date:9/2/2014)... true that digital distribution of media will have ... at least when file sizes are large. , ... Yale,s Journal of Industrial Ecology that ... consoles such as PlayStation3. Researchers found that Blu-ray ... gas emissions than game files downloaded over broadband ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... theoretical price of having one's personal genome sequenced just ... $2.2 million, and the goal is to reduce the ... realistic. , The sharp drop is due to a ... (HMS) researchers Jay Shendure, Gregory Porreca, George Church, and ...
... form of a powerful painkiller for a quick and dangerous ... alarm as the number of people dying from an overdose ... than morphine, rises. , Addicts are misusing a clear patch ... into the bloodstream over the course of a few days, ...
... with a Global Information System will provide valuable information ... National Institute of Environmental Health Sciences (NIEHS), one of ... provide the most up-to-date data to public health and ... industry maps, as well as demographic information for local ...
Cached Biology News:A step toward the $1,000 personal genome using readily available lab equipment 2Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3FDA approves child-friendly AIDS medicine 2
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... designed for protein pull-down experiments ... binding proteins. An order of ... agarose beads with 10 nmol ... terminus of the alkyl chain; ...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
Biology Products: